Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 70518-2107

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 70518-2107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Venlafaxine HCI is a type of medication that comes in the form of a 75 mg Extended-Release Capsule. Each package contains 30 capsules, and the manufacturer is Aurcbindo, Nagar, India 505302. The NDC number for this medication is 70518-2107-00, and the source NDC is 65862-0528-30. Please keep this medication away from children, and follow the directional guidelines outlined in the package insert. The medication should be stored at 20-26°C. This product has been repackaged by RemedyRepack Inc. located in Indiana, PA.*

FDA Label Image

Venlafaxine HCl 75mg 70518 2107 01

Venlafaxine HCI is an extended-release medication contained in 30 capsules with a strength of 75 mg each. The NDC number is 70518-2107-01, and the Lot number and Expiry date are not available. The source NDC is 65862-0528-99, and it is manufactured by Aurobindo in India. The medication should be kept out of reach of children and stored between 20-26°C (63-77°F), with excursions allowed up to 15-30°C (59-86°F) [See USP]. Further instructions are available in the package insert. The medication has been repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Venlafaxine HCl 75mg 70518 2107 02

Venlafaxine HCI is a capsule medication in 75mg extended-release form, with 90 capsules per container. The medication is manufactured by Aurobindo in India, and its packaging is handled by RemedyRepack Inc. The product's full instructions are provided in the package insert, and should be kept at a temperature of 20-26°C (63-77°F), with limited excursions permitted to 15-30°C (59-86°F). The product carries an NDC# of 70518-2107-02 and is not expired, but the LOT # is not available. Consumers are advised to store the medication out of the reach of children.*

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

The text contains a list of recommended PK Fold change and 90% CI for the interacting drug cimetane and analyte aniatxine, veniatxine and venistaxing. The recommendation suggests to use cimetane with caution in patients with hypertension, hepatic dysfunction and in elderly patients. The clinical significance of the recommendations on PK Fold change is unknown for the drugs veniatxine and venistaxing. No dose adjustment is required for cimetane. The text does not provide information on the context where these recommendations are relevant.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

FDA Label Image

Chemical Structure (Venlafaxine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.